Oramed Pharmaceuticals Inc.

Director's Dealing • Mar 23, 2022

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
RAKIN KEVIN ORMP ]									X	Director			10% Owner
(Last) (First) (Middle) 36 CHURCH LANE					3. Date of Earliest Transaction (Month/Day/Year) 03/21/2022								below)	Officer (give title		below)	Other (specify
(Street) WESTPORT	CT		06880	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line) X	6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person
(City)		(State)	(Zip)										Form filed by More than One Reporting Person
			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)				2A. Deemed Execution Date, if any (Month/Day/Year)			3. 4. Securities Acquired (A) or Transaction Disposed Of (D) (Instr. 3, 4 and Code (Instr. 5) 8)				Securities Beneficially		5. Amount of Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
							Code	V	Amount	(A) or (D)	Price		Reported	Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common Stock 03/21/2022							S		10,000	D	\$9.4096			46,661	D
			Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned						(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	10. Form: Direct (D)	Ownership or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Security			(A) or of (D) and 5)	Disposed (Instr. 3, 4			3 and 4)	Security (Instr.	Following Reported Transaction(s) (Instr. 4)	(I) (Instr. 4)
		Code V		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

/s/Kevin Rakin 03/22/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.